Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting

Tissue-based map of the human proteome

Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286 · see citing works

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,542 · see citing works

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

O’Rourke, D. M., Nasrallah, M. P., Desai, A. S., Melenhorst, J. J., Mansfield, K. G., Morrissette, J. J. D., Martinez‐Lage, M., Brem, S. S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,812 · see citing works

Toxicities of chimeric antigen receptor T cells: recognition and management

Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,411 · see citing works

Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy

Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156 · see citing works

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016) · Cell · doi:10.1016/j.cell.2016.01.011 · Cited by 1,010 · see citing works

Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience

Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915 · see citing works

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. P., & Sadelain, M. (2012) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 860 · see citing works

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Lamers, C. H., Sleijfer, S., van Steenbergen, S. C. L., van Elzakker, P., Krimpen, B. A. V., Groot, C., Vulto, A. G., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 706 · see citing works

A transient three-plasmid expression system for the production of high titer retroviral vectors

Soneoka, Y., Cannon, P. M., Ramsdale, E. E., Griffiths, J. C., Romano, G., Kingsman, S. M., & Kingsman, A. J. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.4.628 · Cited by 690 · see citing works

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

Wang, X., Chang, W.-C., Wong, C. W., Colcher, D. M., Sherman, M. A., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011) · Blood · doi:10.1182/blood-2011-02-337360 · Cited by 600 · see citing works

Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

Hudecek, M., Stanghellini, M. T. L., Kosasih, P. L., Sommermeyer, D., Jensen, M. C., Rader, C. M., & Riddell, S. R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0330 · Cited by 543 · see citing works

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

Hudecek, M., Sommermeyer, D., Kosasih, P. L., Silva-Benedict, A., Liu, L., Rader, C. M., Jensen, M. C., & Riddell, S. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0127 · Cited by 534 · see citing works

Engineering CAR-T cells: Design concepts

Srivastava, S., & Riddell, S. R. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.06.004 · Cited by 489 · see citing works

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

Wilkie, S., van Schalkwyk, M. C., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. F. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478 · see citing works

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

Kochenderfer, J., & Rosenberg, S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.46 · Cited by 467 · see citing works

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

Grada, Z., Hegde, M. G., Byrd, T. T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458 · see citing works

Mesenchymal Stem Cells in Tissue Repair

DiMarino, A. M., Caplan, A. I., & Bonfield, T. L. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00201 · Cited by 439 · see citing works

Regulation of hematopoietic stem cells by bone marrow stromal cells

Anthony, B. A., & Link, D. C. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.10.002 · Cited by 301 · see citing works

Wnt5a–Ror–Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis

Ho, H. H., Susman, M. W., Bikoff, J. B., Ryu, Y. K., Jonas, A. M., Hu, L. S., Kuruvilla, R., & Greenberg, M. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200421109 · Cited by 272 · see citing works

A perisinusoidal niche for extramedullary haematopoiesis in the spleen

Inra, C. N., Zhou, B. O., Acar, M., Murphy, M. M., Richardson, J. A., Zhao, Z., & Morrison, S. J. (2015) · Nature · doi:10.1038/nature15530 · Cited by 269 · see citing works

The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor

Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, T., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W.-C., Greisman, H. A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283309 · Cited by 266 · see citing works

Gene Expression Commons: An Open Platform for Absolute Gene Expression Profiling

Seita, J., Sahoo, D., Rossi, D. J., Bhattacharya, D., Serwold, T. F., Inlay, M. A., Ehrlich, L. I. R., Fathman, J. W., Dill, D. L., & Weissman, I. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040321 · Cited by 261 · see citing works

Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues

Balakrishnan, A., Goodpaster, T. A., Randolph‐Habecker, J., Hoffstrom, B. G., Jalikis, F. G., Koch, L. K., Berger, C., Kosasih, P. L., Rajan, A., Sommermeyer, D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2083 · Cited by 220 · see citing works

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Srivastava, S., & Riddell, S. R. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701155 · Cited by 219 · see citing works

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia

Choi, M. Y., Widhopf, G. F., Ghia, E. M., Kidwell, R. L., Hasan, M. K., Yu, J., Rassenti, L. Z., Chen, L., Chen, Y., Pittman, E. I., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.05.018 · Cited by 195 · see citing works

Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells

Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C. M., & Riddell, S. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0163 · Cited by 172 · see citing works

Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells

Liu, G., Vijayakumar, S., Grumolato, L., Arroyave, R., Qiao, H., Akiri, G., & Aaronson, S. A. (2009) · The Journal of Cell Biology · doi:10.1083/jcb.200810137 · Cited by 155 · see citing works

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

Choi, M. Y., Widhopf, G. F., Wu, C. C. N., Cui, B., Lao, F. S., Sadarangani, A., Cavagnaro, J. A., Prussak, C. E., Carson, D. A., Jamieson, C. H. M., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.02.010 · Cited by 110 · see citing works

Histopathology of Preclinical Toxicity Studies

(2012) · Elsevier eBooks · doi:10.1016/c2010-0-67226-9 · Cited by 110 · see citing works

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies

Yang, J., Baskar, S., Kwong, K. Y., Kennedy, M. G., Wiestner, A. U., & Rader, C. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021018 · Cited by 97 · see citing works

Nkx2-5+Islet1+ Mesenchymal Precursors Generate Distinct Spleen Stromal Cell Subsets and Participate in Restoring Stromal Network Integrity

Castagnaro, L., Lenti, E., Maruzzelli, S., Spinardi, L., Migliori, E., Farinello, D., Sitia, G., Harrelson, Z., Evans, S. Μ., Guidotti, L. G., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.12.005 · Cited by 94 · see citing works

Expression of ROR1 has prognostic significance in triple negative breast cancer

Chien, H., Ueng, S., Chen, S., Chang, Y., Lin, Y., Lo, Y.-F., Chang, H., Chuang, W., Huang, Y.-T., Cheung, Y., et al. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-1911-3 · Cited by 88 · see citing works

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy

Li, H., & Zhao, Y. (2017) · Protein & Cell · doi:10.1007/s13238-017-0411-9 · Cited by 82 · see citing works

ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma

Zheng, Y., Ma, R., Zhou, J., Guo, C., Wang, Y., Li, Z.-G., Liu, L., & Peng, Y. (2016) · Scientific Reports · doi:10.1038/srep36447 · Cited by 81 · see citing works

Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease

Potratz, J. C., Tillmanns, A. E., Berning, P., Korsching, E., Schaefer, C., Lechtape, B., Schleithoff, C., Unland, R., Schäfer, K.-L., Müller‐Tidow, C., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.009 · Cited by 45 · see citing works

Stromal Cell Subsets Directing Neonatal Spleen Regeneration

Castan, L., & Watanabe, T. (2017) · Scientific Reports · doi:10.1038/srep40401 · Cited by 24 · see citing works

Tumour-intrinsic resistance to immune checkpoint blockade

Kalbasi, A. K., & Ribas, A. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,491 · see citing works

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,477 · see citing works

Natural killer cells in antitumour adoptive cell immunotherapy

Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 784 · see citing works

Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer

Luu, M., Riester, Z., Baldrich, A., Reichardt, N., Yuille, S., Busetti, A., Klein, M., Wempe, A., Leister, H., Raifer, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24331-1 · Cited by 771 · see citing works

CAR immune cells: design principles, resistance and the next generation

Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 673 · see citing works

Engineering CAR-T Cells for Next-Generation Cancer Therapy

Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 644 · see citing works

Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours

Flugel, C. L., Majzner, R. G., Krenciute, G., Dotti, G., Riddell, S. R., Wagner, D. L., & Abou‐El‐Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00704-3 · Cited by 571 · see citing works

Navigating CAR-T cells through the solid-tumour microenvironment

Hou, A. J., Chen, L. C., & Chen, Y. Y. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00189-2 · Cited by 556 · see citing works

SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma

Choe, J. H., Watchmaker, P., Simic, M., Gilbert, R. D., Li, A. W., Krasnow, N., Downey, K. M., Yu, W., Carrera, D. A., Celli, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe7378 · Cited by 483 · see citing works

The Emerging Landscape of Immune Cell Therapies

Weber, E. W., Maus, M. V., & Mackall, C. L. (2020) · Cell · doi:10.1016/j.cell.2020.03.001 · Cited by 445 · see citing works

CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?

Wagner, J., Wickman, E., DeRenzo, C. C., & Gottschalk, S. M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.015 · Cited by 383 · see citing works

Engineering living therapeutics with synthetic biology

Cubillos-Ruiz, A., Guo, T., Sokolovska, A., Miller, P., Collins, J. J., Lu, T. K., & Lora, J. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00285-3 · Cited by 371 · see citing works

Co-opting signalling molecules enables logic-gated control of CAR T cells

Tousley, A. M., Rotiroti, M. C., Labanieh, L., Rysavy, L. W., Kim, W., Lareau, C. A., Sotillo, E., Weber, E. W., Rietberg, S. P., Dalton, G. N., et al. (2023) · Nature · doi:10.1038/s41586-023-05778-2 · Cited by 336 · see citing works

Immunogenic Chemotherapy Enhances Recruitment of CAR-T Cells to Lung Tumors and Improves Antitumor Efficacy when Combined with Checkpoint Blockade

Srivastava, S., Furlan, S. N., Jaeger-Ruckstuhl, C. A., Sarvothama, M., Berger, C., Smythe, K. S., Garrison, S. M., Specht, J. M., Lee, S. M., Amezquita, R. A., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.11.005 · Cited by 325 · see citing works

Understanding and treating the inflammatory adverse events of cancer immunotherapy

Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319 · see citing works

Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity

Yu, S., Yi, M., Qin, S., & Wu, K. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1057-4 · Cited by 265 · see citing works

Multispecific drugs herald a new era of biopharmaceutical innovation

Deshaies, R. J. (2020) · Nature · doi:10.1038/s41586-020-2168-1 · Cited by 262 · see citing works

Challenges and new technologies in adoptive cell therapy

Zhang, P., Zhang, G., & Wan, X. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01492-8 · Cited by 271 · see citing works

Developing neoantigen-targeted T cell–based treatments for solid tumors

Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 237 · see citing works

Enhanced safety and efficacy of protease-regulated CAR-T cell receptors

Labanieh, L., Majzner, R. G., Klysz, D. D., Sotillo, E., Fisher, C., Vilches-Moure, J. G., Pacheco, K. Z., Malipatlolla, M. B., Xu, P., Hui, J. H., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.041 · Cited by 227 · see citing works

Designed protein logic to target cells with precise combinations of surface antigens

Lajoie, M. J., Boyken, S. E., Salter, A. I., Bruffey, J., Rajan, A., Langan, R. A., Olshefsky, A., Muhunthan, V., Bick, M. J., Gewe, M. M., et al. (2020) · Science · doi:10.1126/science.aba6527 · Cited by 214 · see citing works

Gene editing for immune cell therapies

Bailey, S. R., & Maus, M. V. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0137-8 · Cited by 202 · see citing works

Modular design of synthetic receptors for programmed gene regulation in cell therapies

Zhu, I., Liu, R., Garcia, J. M., Wittsten, A. H., Piraner, D. I., Alavi, J., Israni, D. V., Liu, B., Khalil, A. S., & Roybal, K. T. (2022) · Cell · doi:10.1016/j.cell.2022.03.023 · Cited by 202 · see citing works

Cancer immunotherapy: Challenges and limitations

Taefehshokr, S., Parhizkar, A., Hayati, S., Mousapour, M., Mahmoudpour, A., Eid, L. E., Rahmanpour, D., Fattahi, S., Shabani, H., & Taefehshokr, N. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153723 · Cited by 198 · see citing works

Arming CAR-T cells with cytokines and more: Innovations in the fourth-generation CAR-T development

Tang, L., Pan, S. D., Wei, X., Xu, X., & Wei, Q. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.09.021 · Cited by 201 · see citing works

Engineering a Second‐Order DNA Logic‐Gated Nanorobot to Sense and Release on Live Cell Membranes for Multiplexed Diagnosis and Synergistic Therapy

Wang, D., Li, S., Zhao, Z., Zhang, X., & Tan, W. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202103993 · Cited by 179 · see citing works

The Notch signaling pathway: a potential target for cancer immunotherapy

Li, X., Yan, X., Wang, Y., Kaur, B., Han, H., & Yu, J. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01439-z · Cited by 174 · see citing works

Inefficient CAR-proximal signaling blunts antigen sensitivity

Gudipati, V., Rydzek, J., Doel-Perez, I., Gonçalves, V. D. R., Scharf, L., Königsberger, S., Lobner, E., Kunert, R., Einsele, H., Stockinger, H. S. J., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0719-0 · Cited by 162 · see citing works

Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating

Hamieh, M., Mansilla‐Soto, J., Rivière, I., & Sadelain, M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0101 · Cited by 167 · see citing works

Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma

Moghimi, B., Muthugounder, S., Jambon, S., Tibbetts, R., Hung, L. T., Bassiri, H., Hogarty, M. D., Barrett, D. M., Shimada, H., & Asgharzadeh, S. (2021) · Nature Communications · doi:10.1038/s41467-020-20785-x · Cited by 162 · see citing works

Genetic engineering of T cells for immunotherapy

Ellis, G. I., Sheppard, N. C., & Riley, J. L. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00329-9 · Cited by 166 · see citing works

Cell therapies in the clinic

Wang, L. L., Janes, M. E., Kumbhojkar, N., Kapate, N., Clegg, J. R., Prakash, S., Heavey, M. K., Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10214 · Cited by 162 · see citing works

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Chen, T. R., Wang, M., Chen, Y., & Liu, Y. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03315-3 · Cited by 157 · see citing works

Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control

Miller, I. C., Zamat, A. H., Sun, L.-K., Phuengkham, H., Harris, A. M., Gamboa, L., Yang, J., Murad, J. P., Priceman, S. J., & Kwong, G. A. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00781-2 · Cited by 148 · see citing works

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Alnefaie, A., Albogami, S. M., Asiri, Y. A., Ahmad, T., Alotaibi, S. S., Al-Sanea, M. M., & Althobaiti, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.797440 · Cited by 153 · see citing works

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer

Luo, C., Wang, P., He, S., Zhu, J., Shi, Y., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.919072 · Cited by 147 · see citing works

The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention

Menck, K., Heinrichs, S., Baden, C., & Bleckmann, A. (2021) · Cells · doi:10.3390/cells10010142 · Cited by 128 · see citing works

Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers

Kailayangiri, S., Altvater, B., Wiebel, M., Jamitzky, S., & Rössig, C. (2020) · Cancers · doi:10.3390/cancers12051075 · Cited by 124 · see citing works

High-performance multiplex drug-gated CAR circuits

Li, H.-S., Wong, N. M. L., Tague, E. P., Ngo, J. T., Khalil, A. S., & Wong, W. W. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.008 · Cited by 117 · see citing works

The evolution of synthetic receptor systems

Manhas, J., Edelstein, H. I., Leonard, J. N., & Morsut, L. (2022) · Nature Chemical Biology · doi:10.1038/s41589-021-00926-z · Cited by 115 · see citing works

Antigen-dependent IL-12 signaling in CAR T cells promotes regional to systemic disease targeting

Lee, E. H. J., Murad, J. P., Christian, L., Gibson, J., Yamaguchi, Y., Cullen, C., Gumber, D., Park, A. K., Young, C. A., Monroy, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40115-1 · Cited by 118 · see citing works

Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control

Lu, L., Xie, M., Yang, B., Zhao, W., & Cao, J. (2024) · Science Advances · doi:10.1126/sciadv.adj6251 · Cited by 117 · see citing works

Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies

Dannenfelser, R., Allen, G. M., VanderSluis, B., Koegel, A. K., Levinson, S., Stark, S. R., Yao, V., Tadych, A., Troyanskaya, O. G., & Lim, W. A. (2020) · Cell Systems · doi:10.1016/j.cels.2020.08.002 · Cited by 109 · see citing works

Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review

Brandt, L. J. B., Barnkob, M. B., Michaels, Y. S., Heiselberg, J., & Barington, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00326 · Cited by 103 · see citing works

Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function

Salzer, B., Schueller, C. M., Zajc, C. U., Peters, T., Schoeber, M. A., Kovačic, B., Buri, M. C., Lobner, E., Dushek, O., Huppa, J. B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17970-3 · Cited by 102 · see citing works

Mechanisms of CAR T cell exhaustion and current counteraction strategies

Zhu, X., Li, Q., & Zhu, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1034257 · Cited by 101 · see citing works

Reprogramming the tumor microenvironment by genome editing for precision cancer therapy

Liu, K., Cui, J., Zhan, Y., Ouyang, Q., Lu, Q., Yang, D., Li, X., & Yin, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01561-5 · Cited by 95 · see citing works

Monitoring of cell-cell communication and contact history in mammals

Zhang, S., Zhao, H., Liu, Z., Liu, K., Zhu, H., Pu, W., He, L., Wang, R. A., & Zhou, B. (2022) · Science · doi:10.1126/science.abo5503 · Cited by 94 · see citing works

Promising approaches in cancer immunotherapy

Taefehshokr, N., Baradaran, B., Baghbanzadeh, A., & Taefehshokr, S. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.11.010 · Cited by 93 · see citing works

Advancing cell-based cancer immunotherapy through stem cell engineering

Li, Y.-R., Dunn, Z. S., Yu, Y., Li, M., Wang, P., & Yang, L. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.02.009 · Cited by 94 · see citing works

Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies

Xie, B., Li, Z., Zhou, J., & Wang, W. (2022) · Cancers · doi:10.3390/cancers14133230 · Cited by 92 · see citing works

Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets

Alard, E. L., Butnariu, A.-B., Grillo, M., Kirkham, C., Zinovkin, D. A., Newnham, L. J., Macciochi, J., & Pranjol, M. Z. I. (2020) · Cancers · doi:10.3390/cancers12071826 · Cited by 86 · see citing works

Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors

Miao, L., Zhang, Z., Ren, Z., Tang, F., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687822 · Cited by 82 · see citing works

Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects

Masoumi, J., Jafarzadeh, A., Abdolalizadeh, J., Khan, H. Z., Jeandet, P., Mirzaei, H., & Mirzaei, H. R. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.015 · Cited by 83 · see citing works

Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma

Schaefer, D., Tomiuk, S., Kuester, L. N., Rawashdeh, W. A., Henze, J., Tischler-Höhle, G., Agorku, D., Brauner, J., Linnartz, C., Lock, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21774-4 · Cited by 80 · see citing works

CAR‐T cell therapy for lung cancer: Potential and perspective

Chen, L., Chen, F., Li, J., Pu, Y., Yang, C., Wang, Y., Lei, Y., & Huang, Y. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14375 · Cited by 77 · see citing works

Targeting loss of heterozygosity for cancer-specific immunotherapy

Hwang, M. S., Mog, B. J., Douglass, J., Pearlman, A. H., Hsiue, E. H.-C., Paul, S., DiNapoli, S. R., Konig, M. F., Pardoll, D. M., Gabelli, S. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022410118 · Cited by 79 · see citing works

Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells

Hiltensperger, M., & Krackhardt, A. M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121030 · Cited by 78 · see citing works

Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease

Chao, Z., Mei, Q., Yang, C., Luo, J., Liu, P., Peng, H., Guo, X., Yin, Z., Li, L., & Wang, Z. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02332-6 · Cited by 81 · see citing works

Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation

Yang, Z., Yu, Z., Cai, Y., Du, R., & Cai, L. (2020) · Communications Biology · doi:10.1038/s42003-020-0848-x · Cited by 75 · see citing works

CAR T-cell therapy for triple-negative breast cancer: Where we are

Xie, Y., Hu, Y., Zhou, N., Yao, C., Wu, L., Liu, L., & Chen, F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.044 · Cited by 75 · see citing works

Synthetic Gene Circuits for Regulation of Next‐Generation Cell‐Based Therapeutics

Teixeira, A. P., & Fussenegger, M. (2023) · Advanced Science · doi:10.1002/advs.202309088 · Cited by 76 · see citing works

CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil

Nasiri, F., Kazemi, M., Mirarefin, S. M. J., Kancha, M. M., Najafabadi, M. A., Salem, F., Shokoohi, S. D., Bakhshi, S. E., Kozani, P. S., & Kozani, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018786 · Cited by 75 · see citing works

CAR-T cell therapy for the treatment of adult high-grade gliomas

Park, S., Maus, M. V., & Choi, B. D. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00753-0 · Cited by 76 · see citing works

CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities

Akhoundi, M., Mohammadi, M., Sahraei, S. S., Sheykhhasan, M., & Hosseini, N. F. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00593-1 · Cited by 65 · see citing works

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

Qu, C., Zhang, H., Cao, H., Tang, L., Mo, H., Liu, F., Zhang, L., Yi, Z., Long, L., Yan, L., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01669-8 · Cited by 67 · see citing works

Immune-Based Therapies in Acute Leukemia

Witkowski, M. T., Lasry, A., Carroll, W. L., & Aifantis, I. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.009 · Cited by 63 · see citing works

Prospects and challenges for use of CAR T cell therapies in solid tumors

Ramakrishna, S., Barsan, V. V., & Mackall, C. L. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1738378 · Cited by 59 · see citing works

The antigen‐binding moiety in the driver's seat of CARs

Hanssens, H., Meeus, F., Veirman, K. D., Breckpot, K., & Devoogdt, N. (2021) · Medicinal Research Reviews · doi:10.1002/med.21818 · Cited by 60 · see citing works

A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo

Sandberg, M. L., Wang, X., Martin, A. D., Nampe, D. P., Gabrelow, G. B., Li, C. Z., McElvain, M. E., Lee, W.-H., Shafaattalab, S., Martire, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm0306 · Cited by 61 · see citing works

Novel strategies to manage CAR-T cell toxicity

Mulvey, A., Trueb, L., Coukos, G., & Arber, C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01100-5 · Cited by 64 · see citing works

PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies

Jie, Y., Liu, G., Feng, L., Li, Y., Mingyan, E., Wu, L., Li, Y., Rong, G., Li, Y., Wei, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.665970 · Cited by 60 · see citing works

To go or not to go? Biological logic gating engineered T cells

Abbott, R. C., Hughes‐Parry, H. E., & Jenkins, M. R. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004185 · Cited by 60 · see citing works

Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy

Tahmasebi, S., Elahi, R., Khosh, E., & Esmaeilzadeh, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02490-9 · Cited by 59 · see citing works

Rethinking cancer targeting strategies in the era of smart cell therapeutics

Allen, G. M., & Lim, W. A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00505-x · Cited by 59 · see citing works

Engineering Next-Generation CAR-T Cells for Better Toxicity Management

Andrea, A. E., Chiron, A., Bessoles, S., & Hacein‐Bey‐Abina, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228620 · Cited by 59 · see citing works

Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies

Jaeger-Ruckstuhl, C. A., Specht, J. M., Voutsinas, J. M., Macmillan, H., Wu, Q. V., Muhunthan, V., Berger, C., Pullarkat, S., Wright, J. H., Yeung, C. C. S., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2172 · Cited by 59 · see citing works

CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success

Fiorenza, S., & Turtle, C. J. (2021) · BioDrugs · doi:10.1007/s40259-021-00477-8 · Cited by 57 · see citing works

Engineered natural killer cells for cancer therapy

Biederstädt, A., & Rezvani, K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.013 · Cited by 59 · see citing works

Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity

Shabaneh, T. B., Stevens, A. R., Stull, S. M., Shimp, K. R., Seaton, B. W., Gad, E. A., Jaeger-Ruckstuhl, C. A., Simon, S., Koehne, A. L., Price, J. P., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008566 · Cited by 60 · see citing works

CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer

Włodarczyk, M., & Pyrzyńska, B. (2022) · Cancers · doi:10.3390/cancers15010117 · Cited by 54 · see citing works

CAR-T cell therapy for lung cancer: a promising but challenging future

Zhong, S., Cui, Y., Liu, Q., & Chen, S. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.118 · Cited by 53 · see citing works

SynNotch CAR-T cell, when synthetic biology and immunology meet again

Shirzadian, M., Moori, S., Rabbani, R., & Rahbarizadeh, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1545270 · Cited by 55 · see citing works

All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy

Lanitis, E., Coukos, G., & Irving, M. B. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.01.009 · Cited by 52 · see citing works

Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy

Ruppel, K. E., Fricke, S., Köhl, U., & Schmiedel, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.822298 · Cited by 46 · see citing works

Current Trends in Cancer Immunotherapy

Filin, I. Y., Solovyeva, V. V., Kitaeva, K. V., Rutland, C. S., & Rizvanov, A. A. (2020) · Biomedicines · doi:10.3390/biomedicines8120621 · Cited by 50 · see citing works

T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?

Zhou, Q., Tao, X., Xia, S., Guo, F., Chen, P., Xiang, H., & Shang, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00382 · Cited by 49 · see citing works

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

Vo, M.-C., Tran, V.-D.-H., Nguyen, V., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S., & Lee, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01744-9 · Cited by 55 · see citing works

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting

Seitz, C. M., Mittelstaet, J., Atar, D., Hau, J., Reiter, S., Illi, C., Kieble, V., Engert, F., Drees, B., Bender, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.2003532 · Cited by 47 · see citing works

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Celichowski, P., Turi, M., Charvátová, S., Radhakrishnan, D., Feizi, N., Chyra, Z., Šimíček, M., Jelı́nek, T., Bagó, J. R., Hájek, R., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04041-6 · Cited by 46 · see citing works

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer

Kandra, P., Nandigama, R., Eul, B. G., Huber, M., Kobold, S., Seeger, W., Grimminger, F., & Savai, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903562 · Cited by 48 · see citing works

Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing

Balke-Want, H., Keerthi, V., Gkitsas, N., Mancini, A., Kurgan, G., Fowler, C., Xu, P., Liu, X.-K., Asano, K., Patel, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01799-7 · Cited by 41 · see citing works

Boolean logic in synthetic biology and biomaterials: Towards living materials in mammalian cell therapeutics

Bressler, E. M., Adams, S. C., Liu, R., Colson, Y. L., Wong, W. W., & Grinstaff, M. W. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1244 · Cited by 44 · see citing works

Precision off-the-shelf natural killer cell therapies for oncology with logic-gated gene circuits

Frankel, N. W., Deng, H., Yucel, G., Gainer, M., Leemans, N., Lam, A., Li, Y., Hung, M. E., Lee, D., Lee, C.-T., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114145 · Cited by 46 · see citing works

How I treat high-risk acute myeloid leukemia using preemptive adoptive cellular immunotherapy

Biederstädt, A., & Rezvani, K. (2022) · Blood · doi:10.1182/blood.2021012411 · Cited by 44 · see citing works

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Zhang, T., Tai, Z., Miao, F., Zhang, X., Li, J., Zhu, Q., Wei, H., & Chen, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.033 · Cited by 44 · see citing works

CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar

Chen, K., Liu, M., Wang, J., & Fang, S. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9675 · Cited by 46 · see citing works

Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs

Moghanloo, E., Mollanoori, H., Talebi, M., Pashangzadeh, S., Faraji, F., Hadjilooei, F., & Mahmoodzadeh, H. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101070 · Cited by 44 · see citing works

New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry

Maryamchik, E., Gallagher, K., Preffer, F. I., Kadauke, S., & Maus, M. V. (2020) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21880 · Cited by 41 · see citing works

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review

Miao, L., Zhang, J., Huang, B., Zhang, Z., Wang, S., Tang, F., Teng, M., & Li, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.832765 · Cited by 41 · see citing works

Abstract 6111: Reprogramming ROR1 CAR-T cells with SNIPR logic gating promote safety, while keeping anti-tumor efficacy in a tumor-bearing animal model

Deng, L., Wan, Y., Li, J., Ma, J., Zhu, D., & Zhang, H. (2025) · Cancer Research · doi:10.1158/1538-7445.am2025-6111

Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified T Cells

Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C. M., & Riddell, S. R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0163 · Cited by 172 · see citing works

Research Article Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor–Modified

Cells, T., Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C. M., & Riddell, S. R. (2016)

Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies

Lee, B. K., Wan, Y., Chin, L., Deng, L., Deng, M., Leung, T. M., Ma, J., & Zhang, H. (2022) · Cancers · doi:10.3390/cancers14153618 · Cited by 23 · see citing works

Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity

Vogt, K. C., Silberman, P. C., Lin, Q., Han, J. E., Laflin, A. D., Gellineau, H. A., Heller, D. A., & Scheinberg, D. A. (2025) · Science Advances · doi:10.1126/sciadv.ads3403 · Cited by 30 · see citing works